The importance of patient-specific factors for hepatic drug response and toxicity

International Journal of Molecular Sciences

Volumn 17, Issue 10, 2016, Pages

  Lauschke, Volker M ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Drug induced liver injury; Hepatotoxicity; Liver disease; Pharmacogenetics

Indexed keywords

BROMFENAC; FASIGLIFAM; FIALURIDINE; PEMOLINE; TROGLITAZONE;

AGRANULOCYTOSIS; CYP2D6 GENE; DNA DAMAGE; DRESS SYNDROME; DRUG METABOLISM; DRUG RESPONSE; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; LIPID METABOLISM; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; MITOCHONDRIAL RESPIRATION; PROTEIN PHOSPHORYLATION; REVIEW; SLCO1B1 GENE; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; UGT1A1 GENE; ADVERSE DRUG REACTION; BIOLOGICAL MODEL; INJURIES; LIVER; PATHOLOGY; PHARMACOGENETICS; TOXIC HEPATITIS;

CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIVER; LIVER DISEASES; PATIENT-SPECIFIC MODELING; PHARMACOGENETICS; STEVENS-JOHNSON SYNDROME;

EID: 84992530215     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17101714     Document Type: Review

References (207)

1. Spear, B.B.; Heath-Chiozzi, M.; Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 2001, 7, 201–204.
2. Sim, S.C.; Kacevska, M.; Ingelman-Sundberg, M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenom. J. 2012, 13, 1–11.
3. Frueh, F.W.; Amur, S.; Mummaneni, P.; Epstein, R.S.; Aubert, R.E.; DeLuca, T.M.; Verbrugge, R.R.; Burckart, G.J.; Lesko, L.J. Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use. Pharmacotherapy 2008, 28, 992–998.
4. Ehmann, F.; Caneva, L.; Prasad, K.; Paulmichl, M.; Maliepaard, M.; Llerena, A.; Ingelman-Sundberg, M.; Papaluca-Amati, M. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenom. J. 2015, 15, 201–210.
5. Haga, S.B.; Mills, R.; Moaddeb, J. Pharmacogenetic information for patients on drug labels. Pharmacogenom. Pers. Med. 2014, 7, 297–305.
6. Carr, D.; Alfirevic, A.; Pirmohamed, M. Pharmacogenomics: Current State-of-the-Art. Genes 2014, 5, 430–443.
7. Lauschke, V.M.; Ingelman-Sundberg, M. Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics 2016, 17, 917–924.
8. CPIC Guidelines for Gene-Drug Interactions. Available online: https://cpicpgx.org/genes-drugs (accessed on 12 July 2016).
9. Fujikura, K.; Ingelman-Sundberg, M.; Lauschke, V.M. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet. Genom. 2015, 25, 584–594.
10. Gordon, A.S.; Tabor, H.K.; Johnson, A.D.; Snively, B.M.; Assimes, T.L.; Auer, P.L.; Ioannidis, J.P.A.; Peters, U.; Robinson, J.G.; Sucheston, L.E.; et al. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. Hum. Mol. Genet. 2014, 23, 1957–1963.
11. Kozyra, M.; Ingelman-Sundberg, M.; Lauschke, V.M. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet. Med. 2016.
12. Lauschke, V.M.; Ingelman-Sundberg, M. Precision Medicine and Rare Genetic Variants. Trends Pharmacol. Sci. 2016, 37, 85–86.
13. Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A.K.; Walley, T.J.; Farrar, K.; Park, B.K.; Breckenridge, A.M. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. Br. Med. J. 2004, 329, 15–19.
14. Impicciatore, P.; Choonara, I.; Clarkson, A.; Provasi, D.; Pandolfini, C.; Bonati, M. Incidence of adverse drug reactions in paediatric in/out-patients: A systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol. 2001, 52, 77–83.
15. Routledge, P.A.; O’Mahony, M.S.; Woodhouse, K.W. Adverse drug reactions in elderly patients. Br. J. Clin. Pharmacol. 2003, 57, 121–126.
16. Budnitz, D.S.; Shehab, N.; Kegler, S.R.; Richards, C.L. Medication use leading to emergency department visits for adverse drug events in older adults. Ann. Intern. Med. 2007, 147, 755–765.
17. Bates, D.W.; Spell, N.; Cullen, D.J.; Burdick, E.; Laird, N.; Petersen, L.A.; Small, S.D.; Sweitzer, B.J.; Leape, L.L. The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. J. Am. Med. Assoc. 1997, 277, 307–311.
18. Gautier, S.; Bachelet, H.; Bordet, R.; Caron, J. The cost of adverse drug reactions. Exp. Opin. Pharmacother. 2005, 4, 319–326.
19. Hug, B.L.; Keohane, C.; Seger, D.L.; Yoon, C.; Bates, D.W. The costs of adverse drug events in community hospitals. Jt. Comm. J. Qual. Patient Saf. 2012, 38, 120–126.
20. Johnson, J.A.; Bootman, J.L. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am. J. Health Syst. Pharm. 1997, 54, 554–558.
21. Faich, G.A.; Knapp, D.; Dreis, M.; Turner, W. National adverse drug reaction surveillance: 1985. J. Am. Med. Assoc. 1987, 257, 2068–2070.
22. Goettler, M.; Schneeweiss, S.; Hasford, J. Adverse drug reaction monitoring-cost and benefit considerations. Part II: Cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol. Drug Saf. 1997, 6, S79–S90.
23. Cook, D.; Brown, D.; Alexander, R.; March, R.; Morgan, P.; Satterthwaite, G.; Pangalos, M.N. Lessons learned from the fate of AstraZeneca’s drug pipeline: A five-dimensional framework. Nat. Rev. Drug Discov. 2014, 13, 419–431.
24. Manning, F.J.; Swartz, M. Review of the Fialuridine (FIAU) Clinical Trials; National Academies Press: Atlanta, GA, USA, 1995.
25. Kaku, K.; Enya, K.; Nakaya, R.; Ohira, T.; Matsuno, R. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: A randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes. Metab. 2015, 17, 675–681.
26. Lasser, K.E.; Allen, P.D.; Woolhandler, S.J.; Himmelstein, D.U.; Wolfe, S.M.; Bor, D.H. Timing of new black box warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 2002, 287, 2215–2220.
27. Amstutz, U.; Froehlich, T.K.; Largiadèr, C.R. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011, 12, 1321–1336.
28. Evans, W.E.; Hon, Y.Y.; Bomgaars, L.; Coutre, S.; Holdsworth, M.; Janco, R.; Kalwinsky, D.; Keller, F.; Khatib, Z.; Margolin, J.; et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 2001, 19, 2293–2301.
29. Lennard, L. TPMT in the treatment of Crohn’s disease with azathioprine. Gut 2002, 51, 143–146.
30. Gasche, Y.; Daali, Y.; Fathi, M.; Chiappe, A.; Cottini, S.; Dayer, P.; Desmeules, J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 2004, 351, 2827–2831.
31. Innocenti, F.; Undevia, S.D.; Iyer, L.; Chen, P.X.; Das, S.; Kocherginsky, M.; Karrison, T.; Janisch, L.; Ramírez, J.; Rudin, C.M.; et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 2004, 22, 1382–1388.
32. Wang, G.; Lei, H.-P.; Li, Z.; Tan, Z.-R.; Guo, D.; Fan, L.; Chen, Y.; Hu, D.-L.; Wang, D.; Zhou, H.-H. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur. J. Clin. Pharmacol. 2008, 65, 281–285.
33. Holmes, M.V.; Perel, P.; Shah, T.; Hingorani, A.D.; Casas, J.P. CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis. J. Am. Med. Assoc. 2011, 306, 2704–2714.
34. Johnson, J.A.; Gong, L.; Whirl-Carrillo, M.; Gage, B.F.; Scott, S.A.; Stein, C.M.; Anderson, J.L.; Kimmel, S.E.; Lee, M.T.M.; Pirmohamed, M.; et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clin. Pharmacol. Ther. 2011, 90, 625–629.
35. Furuta, T.; Ohashi, K.; Kamata, T.; Takashima, M.; Kosuge, K.; Kawasaki, T.; Hanai, H.; Kubota, T.; Ishizaki, T.; Kaneko, E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 1998, 129, 1027–1030.
36. Furuta, T.; Shirai, N.; Takashima, M.; Xiao, F.; Hanai, H.; Sugimura, H.; Ohashi, K.; Ishizaki, T.; Kaneko, E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001, 69, 158–168.
37. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy—A genomewide study. N. Engl. J. Med. 2008, 359, 789–799.
38. Wang, L.; McLeod, H.L.; Weinshilboum, R.M. Genomics and drug response. N. Engl. J. Med. 2011, 364, 1144–1153.
39. Hertz, D.L.; Rae, J. Pharmacogenetics of Cancer Drugs. Annu. Rev. Med. 2015, 66, 65–81.
40. Relling, M.V.; Evans, W.E. Pharmacogenomics in the clinic. Nature 2015, 526, 343–350.
41. Abecasis, G.R.; Chakravarti, A.; Donnelly, P.; Eichler, E.E.; Gabriel, S.B.; Hurles, M.E.; Mardis, E.R.; Nickerson, D.A.; Gibbs, R.A.; Boerwinkle, E.; et al. A global reference for human genetic variation. Nature 2015, 526, 68–74.
42. Tennessen, J.A.; Bigham, A.W.; O’Connor, T.D.; Fu, W.; Kenny, E.E.; Gravel, S.; McGee, S.; Do, R.; Liu, X.; Jun, G.; et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012, 337, 64–69.
43. Perry, J.R.B.; Xu, C.; Lawson, D.; Hendricks, A.E.; Barroso, I.; Hurles, M.E.; Greenwood, C.M.T.; Bala, S.; Clapham, P.; Coates, G.; et al. The UK10K project identifies rare variants in health and disease. Nature 2015, 526, 82–90.
44. Ragoussis, J. Genotyping Technologies for Genetic Research. Annu. Rev. Genom. Hum. Genet. 2009, 10, 117–133.
45. Manolio, T.A. Bringing genome-wide association findings into clinical use. Nat. Rev. Genet. 2013, 14, 549–558.
46. Matthaei, J.; Brockmöller, J.; Tzvetkov, M.V.; Sehrt, D.; Sachse-Seeboth, C.; Hjelmborg, J.B.; Möller, S.; Halekoh, U.; Hofmann, U.; Schwab, M.; et al. Heritability of metoprolol and torsemide pharmacokinetics. Clin. Pharmacol. Ther. 2015, 98, 611–621.
47. Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005, 4, 489–499.
48. Dobo, K.L.; Obach, R.S.; Luffer-Atlas, D.; Bercu, J.P. A Strategy for the Risk Assessment of Human Genotoxic Metabolites. Chem. Res. Toxicol. 2009, 22, 348–356.
49. Orr, S.T.M.; Ripp, S.L.; Ballard, T.E.; Henderson, J.L.; Scott, D.O.; Obach, R.S.; Sun, H.; Kalgutkar, A.S. Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks. J. Med. Chem. 2012, 55, 4896–4933.
50. Kitteringham, N.R.; Kenna, J.G.; Park, B.K. Detection of autoantibodies directed against human hepatic endoplasmic reticulum in sera from patients with halothane-associated hepatitis. Br. J. Clin. Pharmacol. 1995, 40, 379–386.
51. Cheng, L.; You, Q.; Yin, H.; Holt, M.P.; Ju, C. Involvement of natural killer T-cells in halothane-induced liver injury in mice. Biochem. Pharmacol. 2010, 80, 255–261.
52. Boelsterli, U.A. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr. Drug Metab. 2002, 3, 439–450.
53. Aithal, G.P.; Ramsay, L.; Daly, A.K.; Sonchit, N.; Leathart, J.B.S.; Alexander, G.; Kenna, J.G.; Caldwell, J.; Day, C.P. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004, 39, 1430–1440.
54. Kalgutkar, A.S.; Dalvie, D. Predicting Toxicities of Reactive Metabolite-Positive Drug Candidates. Annu. Rev. Pharmacol. Toxicol. 2015, 55, 35–54.
55. Hinson, J.A.; Roberts, D.W.; James, L.P. Adverse Drug Reactions (Handbook of Experimental Pharmacology), 1st ed.; Springer: Berlin/Heidelberg, Germany, 2009; Volume 196, pp. 369–405.
56. Koen, Y.M.; Sarma, D.; Williams, T.D.; Galeva, N.A.; Obach, R.S.; Hanzlik, R.P. Identification of Protein Targets of Reactive Metabolites of Tienilic Acid in Human Hepatocytes. Chem. Res. Toxicol. 2012, 25, 1145–1154.
57. Pessayre, D.; Fromenty, B.; Berson, A.; Robin, M.-A.; Lettéron, P.; Moreau, R.; Mansouri, A. Central role of mitochondria in drug-induced liver injury. Drug Metab. Rev. 2012, 44, 34–87.
58. Watmough, N.J.; Bindoff, L.A.; Birch-Machin, M.A.; Jackson, S.; Bartlett, K.; Ragan, C.I.; Poulton, J.; Gardiner, R.M.; Sherratt, H.S.; Turnbull, D.M. Impaired mitochondrial β-oxidation in a patient with an abnormality of the respiratory chain. Studies in skeletal muscle mitochondria. J. Clin. Investig. 1990, 85, 177–184.
59. Blas-García, A.; Apostolova, N.; Ballesteros, D.; Monleón, D.; Morales, J.M.; Rocha, M.; Victor, V.M.; Esplugues, J.V. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010, 52, 115–125.
60. Dykens, J.A.; Jamieson, J.D.; Marroquin, L.D.; Nadanaciva, S.; Xu, J.J.; Dunn, M.C.; Smith, A.R.; Will, Y. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 2008, 103, 335–345.
61. Berson, A.; Schmets, L.; Fisch, C.; Fau, D.; Wolf, C.; Fromenty, B.; Deschamps, D.; Pessayre, D. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen. J. Pharmacol. Exp. Ther. 1994, 270, 167–176.
62. Fromenty, B.; Fisch, C.; Berson, A.; Letteron, P.; Larrey, D.; Pessayre, D. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J. Pharmacol. Exp. Ther. 1990, 255, 1377–1384.
63. Neve, E.P.A.; Köfeler, H.; Hendriks, D.F.G.; Nordling, Å.; Gogvadze, V.; Mkrtchian, S.; Näslund, E.; Ingelman-Sundberg, M. Expression and Function of mARC: Roles in Lipogenesis and Metabolic Activation of Ximelagatran. PLoS ONE 2015, 10, e0138487.
64. Kon, K.; Kim, J.-S.; Jaeschke, H.; Lemasters, J.J. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 2004, 40, 1170–1179.
65. Berson, A.; Descatoire, V.; Sutton, A.; Fau, D.; Maulny, B.; Vadrot, N.; Feldmann, G.; Berthon, B.; Tordjmann, T.; Pessayre, D. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: Role of mitochondrial permeability transition and metabolic activation. J. Pharmacol. Exp. Ther. 2001, 299, 793–800.
66. Masubuchi, Y.; Nakayama, S.; Horie, T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 2002, 35, 544–551.
67. Balakirev, M.Y.; Zimmer, G. Mitochondrial injury by disulfiram: Two different mechanisms of the mitochondrial permeability transition. Chem. Biol. Interact. 2001, 138, 299–311.
68. Mingatto, F.E.; dos Santos, A.C.; Rodrigues, T.; Pigoso, A.A.; Uyemura, S.A.; Curti, C. Effects of nimesulide and its reduced metabolite on mitochondria. Br. J. Pharmacol. 2000, 131, 1154–1160.
69. Trost, L.C.; Lemasters, J.J. The mitochondrial permeability transition: A new pathophysiological mechanism for Reye’s syndrome and toxic liver injury. J. Pharmacol. Exp. Ther. 1996, 278, 1000–1005.
70. Tirmenstein, M.A.; Hu, C.X.; Gales, T.L.; Maleeff, B.E.; Narayanan, P.K.; Kurali, E.; Hart, T.K.; Thomas, H.C.; Schwartz, L.W. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 2002, 69, 131–138.
71. Lim, P.L.K.; Liu, J.; Go, M.L.; Boelsterli, U.A. The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol. Sci. 2008, 101, 341–349.
72. Meyers, L.L.; Beierschmitt, W.P.; Khairallah, E.A.; Cohen, S.D. Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol. Appl. Pharmacol. 1988, 93, 378–387.
73. Donnelly, P.J.; Walker, R.M.; Racz, W.J. Inhibition of mitochondrial respiration in vivo is an early event in acetaminophen-induced hepatotoxicity. Arch. Toxicol. 1994, 68, 110–118.
74. Lee, K.K.; Imaizumi, N.; Chamberland, S.R.; Alder, N.N.; Boelsterli, U.A. Targeting mitochondria with methylene blue protects mice against acetaminophen-induced liver injury. Hepatology 2015, 61, 326–336.
75. Berson, A.; Fau, D.; Fornacciari, R.; Degove-Goddard, P.; Sutton, A.; Descatoire, V.; Haouzi, D.; Letteron, P.; Moreau, A.; Feldmann, G.; et al. Mechanisms for experimental buprenorphine hepatotoxicity: Major role of mitochondrial dysfunction versus metabolic activation. J. Hepatol. 2001, 34, 261–269.
76. Yamamoto, N.; Oliveira, M.B.; Campello Ade, P.; Lopes, L.C.; Klüppel, M.L. Methotrexate: Studies on the cellular metabolism. I. Effect on mitochondrial oxygen uptake and oxidative phosphorylation. Cell Biochem. Funct. 1988, 6, 61–66.
77. Deschamps, D.; DeBeco, V.; Fisch, C.; Fromenty, B.; Guillouzo, A.; Pessayre, D. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: Possible role in pseudoalcoholic liver lesions. Hepatology 1994, 19, 948–961.
78. Cardoso, C.M.P.; Custódio, J.B.A.; Almeida, L.M.; Moreno, A.J.M. Mechanisms of the Deleterious Effects of Tamoxifen on Mitochondrial Respiration Rate and Phosphorylation Efficiency. Toxicol. Appl. Pharmacol. 2001, 176, 145–152.
79. Larosche, I.; Lettéron, P.; Fromenty, B.; Vadrot, N.; Abbey-Toby, A.; Feldmann, G.; Pessayre, D.; Mansouri, A. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J. Pharmacol. Exp. Ther. 2007, 321, 526–535.
80. Pious, D.A.; Hawley, P. Effect of antibiotics on respiration in human cells. Pediatr. Res. 1972, 6, 687–692.
81. Dabadie, P.; Bendriss, P.; Erny, P.; Mazat, J.P. Uncoupling effects of local anesthetics on rat liver mitochondria. FEBS Lett. 1987, 226, 77–82.
82. Ponsoda, X.; Bort, R.; Jover, R.; Gómez-Lechón, M.J.; Castell, J.V. Molecular mechanism of diclofenac hepatotoxicity: Association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol. in Vitro 1995, 9, 439–444.
83. Syed, M.; Skonberg, C.; Hansen, S.H. Mitochondrial toxicity of diclofenac and its metabolites via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria: Possible role in drug induced liver injury (DILI). Toxicol. in Vitro 2016, 31, 93–102.
84. Mingatto, F.E.; Rodrigues, T.; Pigoso, A.A.; Uyemura, S.A.; Curti, C.; Santos, A.C. The critical role of mitochondrial energetic impairment in the toxicity of nimesulide to hepatocytes. J. Pharmacol. Exp. Ther. 2002, 303, 601–607.
85. Berson, A.; Renault, S.; Letteron, P.; Robin, M.A.; Fromenty, B.; Fau, D.; Le Bot, M.A.; Riché, C.; Durand-Schneider, A.M.; Feldmann, G.; et al. Uncoupling of rat and human mitochondria: A possible explanation for tacrine-induced liver dysfunction. Gastroenterology 1996, 110, 1878–1890.
86. Walker, U.A.; Bäuerle, J.; Laguno, M.; Murillas, J.; Mauss, S.; Schmutz, G.; Setzer, B.; Miquel, R.; Gatell, J.M.; Mallolas, J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004, 39, 311–317.
87. McKenzie, R.; Fried, M.W.; Sallie, R.; Conjeevaram, H.; Di Bisceglie, A.M.; Park, Y.; Savarese, B.; Kleiner, D.; Tsokos, M.; Luciano, C. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 1995, 333, 1099–1105.
88. Mansouri, A.; Haouzi, D.; Descatoire, V.; Demeilliers, C.; Sutton, A.; Vadrot, N.; Fromenty, B.; Feldmann, G.; Pessayre, D.; Berson, A. Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver. Hepatology 2003, 38, 715–725.
89. Rachek, L.I.; Yuzefovych, L.V.; LeDoux, S.P.; Julie, N.L.; Wilson, G.L. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol. Appl. Pharmacol. 2009, 240, 348–354.
90. De la Asunción, J.G.; del Olmo, M.L.; Sastre, J.; Pallardó, F.V.; Viña, J. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 1999, 29, 985–987.
91. Le Dinh, T.; Fréneaux, E.; Labbe, G.; Letteron, P.; Degott, C.; Genève, J.; Berson, A.; Larrey, D.; Pessayre, D. Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther. 1988, 247, 745–750.
92. Kennedy, J.A.; Unger, S.A.; Horowitz, J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 1996, 52, 273–280.
93. Fréneaux, E.; Fromenty, B.; Berson, A.; Labbe, G.; Degott, C.; Letteron, P.; Larrey, D.; Pessayre, D. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids. J. Pharmacol. Exp. Ther. 1990, 255, 529–535.
94. Baldwin, G.S.; Murphy, V.J.; Yang, Z.; Hashimoto, T. Binding of nonsteroidal antiinflammatory drugs to the alpha-subunit of the trifunctional protein of long chain fatty acid oxidation. J. Pharmacol. Exp. Ther. 1998, 286, 1110–1114.
95. Ulrich, R.G.; Bacon, J.A.; Cramer, C.T.; Petrella, D.K.; Sun, E.L.; Meglasson, M.D.; Holmuhamedov, E. Disruption of mitochondrial activities in rabbit and human hepatocytes by a quinoxalinone anxiolytic and its carboxylic acid metabolite. Toxicology 1998, 131, 33–47.
96. Genève, J.; Hayat-Bonan, B.; Labbe, G.; Degott, C.; Letteron, P.; Fréneaux, E.; Le Dinh, T.; Larrey, D.; Pessayre, D. Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J. Pharmacol. Exp. Ther. 1987, 242, 1133–1137.
97. Deschamps, D.; Fisch, C.; Fromenty, B.; Berson, A.; Degott, C.; Pessayre, D. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids: Possible role in the development of Reye’s syndrome. J. Pharmacol. Exp. Ther. 1991, 259, 894–904.
98. Fréneaux, E.; Labbe, G.; Letteron, P.; Dinh, T.L.; Degott, C.; Genève, J.; Larrey, D.; Pessayre, D. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988, 8, 1056–1062.
99. Fulgencio, J.-P.; Kohl, C.; Girard, J.; Pégorier, J.-P. Troglitazone Inhibits Fatty Acid Oxidation and Esterification, and Gluconeogenesis in Isolated Hepatocytes from Starved Rats. Diabetes 1996, 45, 1556–1562.
100. Aires, C.C.P.; Ijlst, L.; Stet, F.; Prip-Buus, C.; de Almeida, I.T.; Duran, M.; Wanders, R.J.A.; Silva, M.F.B. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem. Pharmacol. 2010, 79, 792–799.
101. Derks, T.G.J.; van Dijk, T.H.; Grefhorst, A.; Rake, J.-P.; Smit, G.P.A.; Kuipers, F.; Reijngoud, D.-J. Inhibition of mitochondrial fatty acid oxidation in vivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. Hepatology 2008, 47, 1032–1042.
102. Khungar, V.; Han, S.-H. A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Curr. Hepat. Rep. 2010, 9, 75–90.
103. Lee, H.; Hanes, J.; Johnson, K.A. Toxicity of Nucleoside Analogues Used to Treat AIDS and the Selectivity of the Mitochondrial DNA Polymerase. Biochemistry 2003, 42, 14711–14719.
104. Lewis, W.; Copeland, W.C.; Day, B.J. Mitochondrial dna depletion, oxidative stress, and mutation: Mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab. Investig. 2001, 81, 777–790.
105. Moullan, N.; Mouchiroud, L.; Wang, X.; Ryu, D.; Williams, E.G.; Mottis, A.; Jovaisaite, V.; Frochaux, M.V.; Quiros, P.M.; Deplancke, B.; et al. Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research. Cell Rep. 2015, 10, 1681–1691.
106. Schultz, J.C.; Adamson, J.S.; Workman, W.W.; Norman, T.D. Fatal Liver Disease after Intravenous Administration of Tetracycline in High Dosage. N. Engl. J. Med. 1963, 269, 999–1004.
107. Adams, D.H.; Ju, C.; Ramaiah, S.K.; Uetrecht, J.; Jaeschke, H. Mechanisms of Immune-Mediated Liver Injury. Toxicol. Sci. 2010, 115, 307–321.
108. Holt, M.P.; Cheng, L.; Ju, C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J. Leukoc. Biol. 2008, 84, 1410–1421.
109. Ju, C.; Reilly, T.P.; Bourdi, M.; Radonovich, M.F.; Brady, J.N.; George, J.W.; Pohl, L.R. Protective Role of Kupffer Cells in Acetaminophen-Induced Hepatic Injury in Mice. Chem. Res. Toxicol. 2002, 15, 1504–1513.
110. Michael, S.L.; Pumford, N.R.; Mayeux, P.R.; Niesman, M.R.; Hinson, J.A. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 1999, 30, 186–195.
111. Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A.M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359, 727–732.
112. Illing, P.T.; Vivian, J.P.; Dudek, N.L.; Kostenko, L.; Chen, Z.; Bharadwaj, M.; Miles, J.J.; Kjer-Nielsen, L.; Gras, S.; Williamson, N.A.; et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012, 486, 554–558.
113. Chessman, D.; Kostenko, L.; Lethborg, T.; Purcell, A.W.; Williamson, N.A.; Chen, Z.; Kjer-Nielsen, L.; Mifsud, N.A.; Tait, B.D.; Holdsworth, R.; et al. Human Leukocyte Antigen Class I-Restricted Activation of CD8+ T-Cells Provides the Immunogenetic Basis of a Systemic Drug Hypersensitivity. Immunity 2008, 28, 822–832.
114. Batchelor, J.R.; Welsh, K.I.; Tinoco, R.M.; Dollery, C.T.; Hughes, G.R.; Bernstein, R.; Ryan, P.; Naish, P.F.; Aber, G.M.; Bing, R.F.; et al. Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility. Lancet 1980, 1, 1107–1109.
115. Dunphy, J.; Oliver, M.; Rands, A.L.; Lovell, C.R.; McHugh, N.J. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br. J. Dermatol. 2000, 142, 461–467.
116. Chung, W.-H.; Hung, S.-I.; Hong, H.-S.; Hsih, M.-S.; Yang, L.-C.; Ho, H.-C.; Wu, J.-Y.; Chen, Y.-T. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004, 428, 486.
117. Tangamornsuksan, W.; Chaiyakunapruk, N.; Somkrua, R.; Lohitnavy, M.; Tassaneeyakul, W. Relationship Between the HLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatol. 2013, 149, 1025–1028.
118. McCormack, M.; Alfirevic, A.; Bourgeois, S.; Farrell, J.J.; Kasperavičite, D.; Carrington, M.; Sills, G.J.; Marson, T.; Jia, X.; de Bakker, P.I.W.; et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 2011, 364, 1134–1143.
119. Ozeki, T.; Mushiroda, T.; Yowang, A.; Takahashi, A.; Kubo, M.; Shirakata, Y.; Ikezawa, Z.; Iijima, M.; Shiohara, T.; Hashimoto, K.; et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 2011, 20, 1034–1041.
120. Locharernkul, C.; Loplumlert, J.; Limotai, C.; Korkij, W.; Desudchit, T.; Tongkobpetch, S.; Kangwanshiratada, O.; Hirankarn, N.; Suphapeetiporn, K.; Shotelersuk, V. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008, 49, 2087–2091.
121. Man, C.B.L.; Kwan, P.; Baum, L.; Yu, E.; Lau, K.M.; Cheng, A.S.H.; Ng, M.H.L. Association between HLA-B*1502 Allele and Antiepileptic Drug-Induced Cutaneous Reactions in Han Chinese. Epilepsia 2007, 48, 1015–1018.
122. Hung, S.-I.; Chung, W.-H.; Liou, L.-B.; Chu, C.-C.; Lin, M.; Huang, H.-P.; Lin, Y.-L.; Lan, J.-L.; Yang, L.-C.; Hong, H.-S.; et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 2005, 102, 4134–4139.
123. Lonjou, C.; Borot, N.; Sekula, P.; Ledger, N.; Thomas, L.; Halevy, S.; Naldi, L.; Bouwes-Bavinck, J.-N.; Sidoroff, A.; de Toma, C.; et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genom. 2008, 18, 99–107.
124. Kaniwa, N.; Saito, Y.; Aihara, M.; Matsunaga, K.; Tohkin, M.; Kurose, K.; Sawada, J.-I.; Furuya, H.; Takahashi, Y.; Muramatsu, M.; et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008, 9, 1617–1622.
125. Tassaneeyakul, W.; Jantararoungtong, T.; Chen, P.; Lin, P.-Y.; Tiamkao, S.; Khunarkornsiri, U.; Chucherd, P.; Konyoung, P.; Vannaprasaht, S.; Choonhakarn, C.; et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genom. 2009, 19, 704–709.
126. Cornejo Castro, E.M.; Carr, D.F.; Jorgensen, A.L.; Alfirevic, A.; Pirmohamed, M. HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity. Pharmacogenet. Genom. 2015, 25, 186–198.
127. Carr, D.F.; Chaponda, M.; Jorgensen, A.L.; Castro, E.C.; van Oosterhout, J.J.; Khoo, S.H.; Lalloo, D.G.; Heyderman, R.S.; Alfirevic, A.; Pirmohamed, M. Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. Clin. Infect. Dis. 2013, 56, 1330–1339.
128. Yunis, J.J.; Corzo, D.; Salazar, M.; Lieberman, J.A.; Howard, A.; Yunis, E.J. HLA associations in clozapine-induced agranulocytosis. Blood 1995, 86, 1177–1183.
129. Goldstein, J.I.; Jarskog, L.F.; Hilliard, C.; Alfirevic, A.; Duncan, L.; Fourches, D.; Huang, H.; Lek, M.; Neale, B.M.; Ripke, S.; et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat. Commun. 2014, 5, 4757.
130. Daly, A.K.; Donaldson, P.T.; Bhatnagar, P.; Shen, Y.; Pe’er, I.; Floratos, A.; Daly, M.J.; Goldstein, D.B.; John, S.; Nelson, M.R.; et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41, 816–819.
131. Kindmark, A.; Jawaid, A.; Harbron, C.G.; Barratt, B.J.; Bengtsson, O.F.; Andersson, T.B.; Carlsson, S.; Cederbrant, K.E.; Gibson, N.J.; Armstrong, M.; et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenom. J. 2007, 8, 186–195.
132. Hautekeete, M.L.; Horsmans, Y.; van Waeyenberge, C.; Demanet, C.; Henrion, J.; Verbist, L.; Brenard, R.; Sempoux, C.; Michielsen, P.P.; Yap, P.; et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999, 117, 1181–1186.
133. O’Donohue, J.; Oien, K.A.; Donaldson, P.; Underhill, J.; Clare, M.; MacSween, R.M.; Mills, P.R. Co-amoxiclav jaundice: Clinical and histological features and HLA class II association. Gut 2000, 47, 717–720.
134. Donaldson, P.T.; Daly, A.K.; Henderson, J.; Graham, J.; Pirmohamed, M.; Bernal, W.; Day, C.P.; Aithal, G.P. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J. Hepatol. 2010, 53, 1049–1053.
135. Lucena, M.I.; Molokhia, M.; Shen, Y.; Urban, T.J.; Aithal, G.P.; Andrade, R.J.; Day, C.P.; Cabello, F.R.; Donaldson, P.T.; Stephens, C.L.; et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141, 338–347.
136. Singer, J.B.; Lewitzky, S.; Leroy, E.; Yang, F.; Zhao, X.; Klickstein, L.; Wright, T.M.; Meyer, J.; Paulding, C.A. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 2010, 42, 711–714.
137. Hirata, K.; Takagi, H.; Yamamoto, M.; Matsumoto, T.; Nishiya, T.; Mori, K.; Shimizu, S.; Masumoto, H.; Okutani, Y. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: A preliminary case-control study. Pharmacogenom. J. 2007, 8, 29–33.
138. Hetherington, S.; McGuirk, S.; Powell, G.; Cutrell, A.; Naderer, O.; Spreen, B.; Lafon, S.; Pearce, G.; Steel, H. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 2001, 23, 1603–1614.
139. Mallal, S.; Phillips, E.; Carosi, G.; Molina, J.-M.; Workman, C.; Tomazic, J.; Jägel-Guedes, E.; Rugina, S.; Kozyrev, O.; Cid, J.F.; et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 2008, 358, 568–579.
140. Hughes, D.A.; Vilar, F.J.; Ward, C.C.; Alfirevic, A.; Park, B.K.; Pirmohamed, M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004, 14, 335–342.
141. Schackman, B.R.; Scott, C.A.; Walensky, R.P.; Losina, E.; Freedberg, K.A.; Sax, P.E. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008, 22, 2025–2033.
142. Wolf, E.; Blankenburg, M.; Bogner, J.R.; Becker, W.; Gorriahn, D.; Mueller, M.C.; Jaeger, H.; Welte, R.; Baudewig, M.; Walli, R.; et al. Cost Impact of Prospective Hla-B*5701-Screening Prior to Abacavir/Lamivudine Fixed Dose Combination Use in Germany. Eur. J. Med. Res. 2010, 15, 145–151.
143. Schoonen, W.M.; Thomas, S.L.; Somers, E.C.; Smeeth, L.; Kim, J.; Evans, S.; Hall, A.J. Do selected drugs increase the risk of lupus? A matched case-control study. Br. J. Clin. Pharmacol. 2010, 70, 588–596.
144. Moser, K.L.; Kelly, J.A.; Lessard, C.J.; Harley, J.B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 2009, 10, 373–379.
145. Graham, R.R.; Ortmann, W.A.; Langefeld, C.D.; Jawaheer, D.; Selby, S.A.; Rodine, P.R.; Baechler, E.C.; Rohlf, K.E.; Shark, K.B.; Espe, K.J.; et al. Visualizing Human Leukocyte Antigen Class II Risk Haplotypes in Human Systemic Lupus Erythematosus. Am. J. Hum. Genet. 2002, 71, 543–553.
146. Fernando, M.M.A.; Stevens, C.R.; Sabeti, P.C.; Walsh, E.C.; McWhinnie, A.J.M.; Shah, A.; Green, T.; Rioux, J.D.; Vyse, T.J. Identification of Two Independent Risk Factors for Lupus within the MHC in United Kingdom Families. PLoS Genet. 2007, 3, e192–e113.
147. International MHC and Autoimmunity Genetics Network; Rioux, J.D.; Goyette, P.; Vyse, T.J.; Hammarström, L.; Fernando, M.M.; Green, T.; de Jager, P.L.; Foisy, S.; Wang, J.; et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc. Natl. Acad. Sci. USA 2009, 106, 18680–18685.
148. Barcellos, L.F.; May, S.L.; Ramsay, P.P.; Quach, H.L.; Lane, J.A.; Nititham, J.; Noble, J.A.; Taylor, K.E.; Quach, D.L.; Chung, S.A.; et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet. 2009, 5, e1000696.
149. De Maat, M.M.R.; ter Heine, R.; Mulder, J.W.; Meenhorst, P.L.; Mairuhu, A.T.A.; van Gorp, E.C.M.; Huitema, A.D.R.; Beijnen, J.H. Incidence and risk factors for nevirapine-associated rash. Eur. J. Clin. Pharmacol. 2003, 59, 457–462.
150. Warren, K.J.; Boxwell, D.E.; Kim, N.Y.; Drolet, B.A. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998, 351, 567–561.
151. Alvir, J.M.J.; Lieberman, J.A.; Safferman, A.Z.; Schwimmer, J.L.; Schaaf, J.A. Clozapine-Induced Agranulocytosis—Incidence and Risk Factors in the United States. N. Engl. J. Med. 1993, 329, 162–167.
152. Phillips, E.J.; Mallal, S.A. HLA-B*5701 and flucloxacillin associated drug-induced liver disease. AIDS 2013, 27, 491–492.
153. Alfirevic, A.; Pirmohamed, M. predictiveg enetic testing for drug-induced liver injury: Considerations of clinical utility. Clin. Pharmacol. Ther. 2009, 92, 376–380.
154. Chalasani, N.; Fontana, R.J.; Bonkovsky, H.L.; Watkins, P.B.; Davern, T.; Serrano, J.; Yang, H.; Rochon, J. Causes, Clinical Features, and Outcomes from a Prospective Study of Drug-Induced Liver Injury in the United States. Gastroenterology 2008, 135, 1924–1934.
155. Stephens, C.; López-Nevot, M.-Á.; Ruiz-Cabello, F.; Ulzurrun, E.; Soriano, G.; Romero-Gómez, M.; Moreno-Casares, A.; Lucena, M.I.; Andrade, R.J. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS ONE 2013, 8, e68111–e68117.
156. Kim, S.-H.; Saide, K.; Farrell, J.; Faulkner, L.; Tailor, A.; Ogese, M.; Daly, A.K.; Pirmohamed, M.; Park, B.K.; Naisbitt, D.J. Characterization of amoxicillin- and clavulanic acid-specific T-cells in patients with amoxicillin-clavulanate-induced liver injury. Hepatology 2015, 62, 887–899.
157. Farid, N.A.; Kurihara, A.; Wrighton, S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 2013, 50, 126–142.
158. Ariyoshi, N.; Iga, Y.; Hirata, K.; Sato, Y.; Miura, G.; Ishii, I.; Nagamori, S.; Kitada, M. Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab. Pharmacokinet. 2010, 25, 298–306.
159. Lee, W.M.; Larrey, D.; Olsson, R.; Lewis, J.H.; Keisu, M.; Auclert, L.; Sheth, S. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005, 28, 351–370.
160. Pentikäinen, P.J.; Neuvonen, P.J.; Jostell, K.G. Pharmacokinetics of Chlormethiazole in healthy-volunteers and patients with cirrhosis of the liver. Eur. J. Clin. Pharmacol. 1980, 17, 275–284.
161. Neugebauer, G.; Gabor, M.; Reiff, K. Pharmacokinetics and bioavailability of carvedilol in patients with liver cirrhosis. Drugs 1988, 36, 148–154.
162. Morgan, D.J.; McLean, A.J. Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease. Hepatology 1991, 14, 1280–1282.
163. Frye, R.F.; Zgheib, N.K.; Matzke, G.R.; Chaves-Gnecco, D.; Rabinovitz, M.; Shaikh, O.S.; Branch, R.A. Liver disease selectively modulates cytochrome P450—mediated metabolism. Clin. Pharmacol. Ther. 2006, 80, 235–245.
164. Kovarik, J.M.; Sabia, H.D.; Figueiredo, J.; Zimmermann, H.; Reynolds, C.; Dilzer, S.C.; Lasseter, K.; Rordorf, C. Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clin. Pharmacol. Ther. 2001, 70, 425–430.
165. Chalasani, N.; Gorski, J.C.; Patel, N.H.; Hall, S.D.; Galinsky, R.E. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts. Hepatology 2001, 34, 1103–1108.
166. Guengerich, F.P.; Turvy, C.G. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 1991, 256, 1189–1194.
167. George, J.; Murray, M.; Byth, K.; Farrell, G.C. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995, 21, 120–128.
168. Shull, H.J.; Wilkinson, G.R.; Johnson, R.; Schenker, S. Normal Disposition of Oxazepam in Acute Viral-Hepatitis and Cirrhosis. Ann. Intern. Med. 1976, 84, 420–425.
169. Klotz, U.; Antonin, K.H.; Brügel, H.; Bieck, P.R. Disposition of Diazepam and Its Major Metabolite Desmethyldiazepam in Patients with Liver-Disease. Clin. Pharmacol. Ther. 1977, 21, 430–436.
170. Crotty, B.; Watson, K.; Desmond, P.V.; Mashford, M.L.; Wood, L.J.; Colman, J.; Dudley, F.J. Hepatic Extraction of Morphine Is Impaired in Cirrhosis. Eur. J. Clin. Pharmacol. 1989, 36, 501–506.
171. Taburet, A.M.; Naveau, S.; Zorza, G.; Colin, J.N.; Delfraissy, J.F.; Chaput, J.C.; Singlas, E. Pharmacokinetics of Zidovudine in Patients with Liver-Cirrhosis. Clin. Pharmacol. Ther. 1990, 47, 731–739.
172. Marcellin, P.; De Bony, F.; Garret, C.; Altman, C.; Boige, V.; Castelnau, C.; Laurent-Puig, P.; Trinchet, J.C.; Rolan, P.; Chen, C.; et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br. J. Clin. Pharmacol. 2002, 51, 410–414.
173. Fisher, C.D.; Lickteig, A.J.; Augustine, L.M.; Ranger-Moore, J.; Jackson, J.P.; Ferguson, S.S.; Cherrington, N.J. Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease. Drug Metab. Dispos. 2009, 37, 2087–2094.
174. Kolwankar, D.; Vuppalanchi, R.; Ethell, B.; Jones, D.R.; Wrighton, S.A.; Hall, S.D.; Chalasani, N. Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity. Clin. Gastroenterol. Hepatol. 2007, 5, 388–393.
175. Orellana, M.; Rodrigo, R.; Varela, N.; Araya, J.; Poniachik, J.; Csendes, A.; Smok, G.; Videla, L.A. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol. Res. 2006, 34, 57–63.
176. Kohjima, M.; Enjoji, M.; Higuchi, N.; Kato, M.; Kotoh, K.; Yoshimoto, T.; Fujino, T.; Yada, M.; Yada, R.; Harada, N.; et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 2007, 20, 351–358.
177. Baker, S.S.; Baker, R.D.; Liu, W.; Nowak, N.J.; Zhu, L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS ONE 2010, 5, e9570.
178. Chalasani, N.; Gorski, J.C.; Asghar, M.S.; Asghar, A.; Foresman, B.; Hall, S.D.; Crabb, D.W. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003, 37, 544–550.
179. Emery, M.G.; Fisher, J.M.; Chien, J.Y.; Kharasch, E.D.; Dellinger, E.P.; Kowdley, K.V.; Thummel, K.E. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003, 38, 428–435.
180. Younossi, Z.M.; Baranova, A.; Ziegler, K.; Del Giacco, L.; Schlauch, K.; Born, T.L.; Elariny, H.; Gorreta, F.; VanMeter, A.; Younoszai, A.; et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005, 42, 665–674.
181. Stepanova, M.; Hossain, N.; Afendy, A.; Perry, K.; Goodman, Z.D.; Baranova, A.; Younossi, Z. Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease. Obes. Surg. 2010, 20, 640–650.
182. Hardwick, R.N.; Fisher, C.D.; Canet, M.J.; Scheffer, G.L.; Cherrington, N.J. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 2011, 39, 2395–2402.
183. Okushin, K.; Tsutsumi, T.; Enooku, K.; Kado, A.; Fujinaga, H.; Moriya, K.; Yotsuyanagi, H.; Koike, K. P0972: Expressions of bile acid transporters are inversely correlated with NAFLD activity score in the liver of patients with non-alcoholic fatty liver disease. J. Hepatol. 2015, 62, S710.
184. Canet, M.J.; Merrell, M.D.; Hardwick, R.N.; Bataille, A.M.; Campion, S.N.; Ferreira, D.W.; Xanthakos, S.A.; Manautou, J.E.; A-Kader, H.H.; Erickson, R.P.; et al. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis. Drug Metabo. Dispos. 2015, 43, 829–835.
185. Murphy, S.K.; Yang, H.; Moylan, C.A.; Pang, H.; Dellinger, A.; Abdelmalek, M.F.; Garrett, M.E.; Koch, A.A.; Suzuki, A.; Tillmann, H.L.; et al. Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2013, 145, 1076–1087.
186. Fisel, P.; Schaeffeler, E.; Schwab, M. DNA Methylation of ADME Genes. Clin. Pharmacol. Ther. 2016, 99, 512–527.
187. Westlind, A.; Löfberg, L.; Tindberg, N.; Andersson, T.B.; Ingelman-Sundberg, M. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 50-upstream regulatory region. Biochem. Biophys. Res. Commun. 1999, 259, 201–205.
188. Ozdemir, V.; Kalow, W.; Tang, B.K.; Paterson, A.D.; Walker, S.E.; Endrenyi, L.; Kashuba, A.D. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000, 10, 373–388.
189. Kacevska, M.; Ivanov, M.; Wyss, A.; Kasela, S.; Milani, L.; Rane, A.; Ingelman-Sundberg, M. DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie 2012, 94, 2338–2344.
190. Ivanov, M.; Kals, M.; Kacevska, M.; Barragan, I.; Kasuga, K.; Rane, A.; Metspalu, A.; Milani, L.; Ingelman-Sundberg, M. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol. 2013, 14, R83.
191. Ivanov, M.; Kals, M.; Lauschke, V.M.; Barragan, I.; Ewels, P.; Käller, M.; Axelsson, T.; Lehtiö, J.; Milani, L.; Ingelman-Sundberg, M. Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: Implications for hepatic gene expression. Nucleic Acids Res. 2016.
192. Dominguez, A.A.; Lim, W.A.; Qi, L.S. Beyond editing: Repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat. Rev. Mol. Cell Biol. 2016, 17, 5–15.
193. Gómez-Lechón, M.J.; Tolosa, L.; Conde, I.; Donato, M.T. Competency of different cell models to predict human hepatotoxic drugs. Exp. Opin. Drug Metab. Toxicol. 2014, 10, 1553–1568.
194. Sison-Young, R.L.; Lauschke, V.M.; Johann, E.; Alexandre, E.; Anthérieu, S.; Aerts, H.; Gerets, H.H.J.; Labbe, G.; Hoët, D.; Dorau, M.; et al. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch. Toxicol. 2016.
195. Treyer, A.; Müsch, A. Hepatocyte polarity. Compr. Physiol. 2013, 3, 243–287.
196. Engler, A.J.; Sen, S.; Sweeney, H.L.; Discher, D.E. Matrix Elasticity Directs Stem Cell Lineage Specification. Cell 2006, 126, 677–689.
197. Rowe, C.; Gerrard, D.T.; Jenkins, R.; Berry, A.; Durkin, K.; Sundstrom, L.; Goldring, C.E.; Park, B.K.; Kitteringham, N.R.; Hanley, K.P.; et al. Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. Hepatology 2013, 58, 799–809.
198. Heslop, J.A.; Rowe, C.; Walsh, J.; Sison-Young, R.; Jenkins, R.; Kamalian, L.; Kia, R.; Hay, D.; Jones, R.P.; Malik, H.Z.; et al. Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. Arch. Toxicol. 2016.
199. Lauschke, V.M.; Vorrink, S.U.; Moro, S.M.; Reyazee, F.; Nordling, Å.; Hendriks, D.F.; Bell, C.C.; Sison-Young, R.; Park, B.K.; Goldring, C.E.; et al. Massive rearrangements of cellular miRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology 2016.
200. Lauschke, V.M.; Hendriks, D.F.; Bell, C.C.; Andersson, T.B.; Ingelman-Sundberg, M. Novel 3D culture systems for studies of liver function and assessments of hepatotoxicity of drugs and drug candidates. Chem. Res. Toxicol. 2016.
201. Tostões, R.M.; Leite, S.B.; Serra, M.; Jensen, J.; Björquist, P.; Carrondo, M.J.T.; Brito, C.; Alves, P.M. Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 2012, 55, 1227–1236.
202. Messner, S.; Agarkova, I.; Moritz, W.; Kelm, J.M. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch. Toxicol. 2012, 87, 209–213.
203. Bell, C.C.; Hendriks, D.F.G.; Moro, S.M.L.; Ellis, E.; Walsh, J.; Renblom, A.; Fredriksson-Puigvert, L.; Dankers, A.C.A.; Jacobs, F.; Snoeys, J.; et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci. Rep. 2016, 6, 25187.
204. Davidson, M.D.; Ballinger, K.R.; Khetani, S.R. Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes. Sci. Rep. 2016, 6, 28178.
205. Warren, J.D.; Xiong, W.; Bunker, A.M.; Vaughn, C.P.; Furtado, L.V.; Roberts, W.L.; Fang, J.C.; Samowitz, W.S.; Heichman, K.A. Septin 9 methylatedDNAis a sensitive and specific blood test for colorectal cancer. BMC Med. 2011, 9, 133.
206. Baden, J.; Green, G.; Painter, J.; Curtin, K.; Markiewicz, J.; Jones, J.; Astacio, T.; Canning, S.; Quijano, J.; Guinto, W.; et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J. Urol. 2009, 182, 1186–1193.
207. Waring, M.J.; Arrowsmith, J.; Leach, A.R.; Leeson, P.D.; Mandrell, S.; Owen, R.M.; Pairaudeau, G.; Pennie, W.D.; Pickett, S.D.; Wang, J.; et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 2015, 14, 475–486.